Two names come up frequently in type 2 diabetes conversations: Trulicity and Ozempic. Both are once-weekly GLP-1 injections, both lower blood sugar, and both carry similar brand-name price tags. But they're not interchangeable — and the differences matter significantly depending on whether you're managing diabetes, pursuing weight loss, or exploring telehealth as your care channel.
This guide covers the clinical data, cost realities, and telehealth access picture so you can have an informed conversation with your provider.
The Quick Comparison
| Trulicity | Ozempic | |
|---|---|---|
| Active ingredient | Dulaglutide | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA-approved for | Type 2 diabetes | Type 2 diabetes; cardiovascular risk reduction |
| FDA approved | 2014 | 2017 |
| Max dose | 4.5mg/week | 2.0mg/week |
| Avg. A1C reduction | ~1.1–1.5% | ~1.5–1.8% |
| Avg. weight loss (trials) | ~1.5–2 kg | ~4–7 kg |
| Brand list price | ~$850–$1,000/month | ~$850–$1,000/month |
| Compounded option? | Not widely available | Yes — widely available through telehealth |
| Telehealth availability | Rare | Widely available |
What Each Drug Is
Trulicity (Dulaglutide)
Trulicity is a GLP-1 receptor agonist developed by Eli Lilly, FDA-approved in 2014 for the management of type 2 diabetes in adults. It works by mimicking the GLP-1 hormone produced naturally after eating — stimulating insulin release, suppressing glucagon, and slowing gastric emptying to reduce post-meal blood sugar spikes.
Key characteristics:
- Administered as a once-weekly subcutaneous injection via autoinjector pen
- Starting dose: 0.75mg/week, with a maintenance target of 1.5mg/week
- Available in higher doses: 3.0mg/week and 4.5mg/week for additional glycemic control
- Also FDA-approved to reduce major adverse cardiovascular events in patients with established cardiovascular disease or multiple risk factors
Trulicity was one of the earlier GLP-1 medications on the market and built a strong prescribing track record through 2018–2022 before semaglutide's weight loss story shifted clinical attention.
Ozempic (Semaglutide)
Ozempic is a GLP-1 receptor agonist developed by Novo Nordisk, FDA-approved in 2017 for type 2 diabetes management and cardiovascular risk reduction. Semaglutide — the active ingredient — is considered a more potent GLP-1 agonist than dulaglutide due to molecular modifications that extend its half-life and receptor binding affinity.
Key characteristics:
- Administered as a once-weekly subcutaneous injection
- Titration schedule: 0.25mg/week (starting) → 0.5mg → 1.0mg → 2.0mg/week maximum
- Semaglutide is also the active ingredient in Wegovy (2.4mg/week, FDA-approved for chronic weight management)
- Compounded semaglutide — the same active ingredient — is widely available through telehealth providers
The weight loss data from semaglutide trials drove an enormous shift in both public awareness and prescribing patterns, making Ozempic's active ingredient arguably the most in-demand GLP-1 medication today.
Efficacy Data: A1C Reduction and Weight Loss
A1C Reduction
Both medications lower blood sugar meaningfully, but clinical trials consistently show semaglutide outperforming dulaglutide on glycemic control.
| Trial | Medication | A1C Reduction (avg.) |
|---|---|---|
| AWARD-1 | Dulaglutide 1.5mg | −1.51% |
| AWARD-6 (head-to-head) | Dulaglutide 1.5mg vs. Liraglutide | −1.42% |
| SUSTAIN-7 (head-to-head) | Semaglutide 1.0mg vs. Dulaglutide 1.5mg | −1.84% vs. −1.36% |
| SUSTAIN-7 | Semaglutide 0.5mg vs. Dulaglutide 0.75mg | −1.45% vs. −1.10% |
The SUSTAIN-7 trial is the most relevant direct comparison. Semaglutide 1.0mg reduced A1C by 0.48 percentage points more than dulaglutide 1.5mg — a clinically meaningful difference.
Weight Loss
The weight loss comparison is starker. SUSTAIN-7 showed:
- Semaglutide 1.0mg: −6.5 kg average weight loss
- Dulaglutide 1.5mg: −3.0 kg average weight loss
- Semaglutide 0.5mg: −4.6 kg average weight loss
- Dulaglutide 0.75mg: −2.3 kg average weight loss
At higher doses used for weight management (semaglutide up to 2.4mg via Wegovy), average weight loss in the STEP trials exceeded 15% of body weight. No comparable weight loss data exists for dulaglutide at high doses.
Clinical bottom line: If glycemic control is the only goal, both are effective. If any degree of weight loss is also a priority, semaglutide has a substantially stronger evidence base.
Side Effects
GLP-1 medications share a common side effect profile because they all work through the same core mechanism.
Common Side Effects (Both Medications)
- Nausea — most common, especially during dose escalation
- Vomiting
- Diarrhea
- Constipation
- Abdominal discomfort or bloating
- Decreased appetite (the intended mechanism, also listed as a side effect)
Most gastrointestinal side effects peak during dose increases and resolve as the body adjusts over 2–4 weeks. Slow titration — the standard protocol at reputable providers — significantly reduces severity.
Trulicity vs. Ozempic: Which Is Better Tolerated?
Head-to-head adverse event data from SUSTAIN-7 showed broadly similar GI tolerability between the two medications, with no statistically significant difference in discontinuation rates due to adverse events. Both were generally well-tolerated in clinical trials.
Some patients report more injection site reactions with Trulicity's autoinjector mechanism, while Ozempic uses a traditional pen-style delivery system. This is a minor consideration for most patients but worth noting for those sensitive to device type.
Serious Risks (Both Medications)
- Pancreatitis — rare but documented; discontinue if symptoms occur
- Gallbladder disease — increased risk with rapid weight loss
- Thyroid C-cell tumors — seen in rodent studies; not established in humans, but both drugs carry a boxed warning
- Diabetic retinopathy complications — documented with semaglutide in patients with pre-existing retinopathy; discuss with your provider
Cost Comparison
Brand-Name List Price
Without insurance, both Trulicity and Ozempic carry brand-name list prices in the same range:
- Trulicity: ~$850–$1,000/month
- Ozempic: ~$850–$1,000/month
GoodRx discount cards can reduce out-of-pocket cost at select pharmacies, but savings vary by location and dose. Neither medication is inexpensive at retail price without insurance.
With Insurance
Both drugs are covered by many commercial insurance plans — but coverage rules differ:
| Medication | Typical Insurance Path |
|---|---|
| Trulicity | Covered for type 2 diabetes; may require step therapy or PA |
| Ozempic | Covered for type 2 diabetes; often requires PA for weight management use |
Manufacturer savings cards can reduce branded copays for commercially insured patients not on government programs.
Compounded Semaglutide: The Telehealth Cost Advantage
This is where the comparison diverges sharply. Semaglutide — the active ingredient in Ozempic — has been available as a compounded injectable through telehealth providers for $99–$450/month. No comparable compounded alternative exists for dulaglutide (Trulicity).
Representative semaglutide pricing through telehealth (compounded):
| Provider | Monthly Cost | Notes |
|---|---|---|
| Belle Health | $119/mo | Flat pricing at all doses |
| Ro | $149/mo | Brand Wegovy also available |
| Henry Meds | $149/mo | No consultation fee |
| Ivim Health | $150/mo | Includes weekly check-ins |
| Found | $159/mo | Includes coaching |
| Hims | $199/mo | Compounded semaglutide |
| Hone Health | $299/mo | Labs included |
If cost is a primary factor in your decision, semaglutide accessed through telehealth is meaningfully more affordable than Trulicity at any price point.
Telehealth Access
Ozempic (Semaglutide): Widely Available
Semaglutide is the most widely available GLP-1 medication through telehealth. The reasons are structural:
- Compounded semaglutide fills an access gap created by Wegovy shortages
- Telehealth platforms are built for weight management — semaglutide serves both diabetes and weight loss use cases
- The active ingredient's cost-effectiveness drives high patient demand
In the TeleHealthAlly provider database, 17+ providers offer semaglutide — compounded, brand Wegovy, or both. Most offer asynchronous or video consultation, shipping to most U.S. states, and ongoing dosage management without requiring in-person visits.
Trulicity (Dulaglutide): Rarely Available Through Telehealth
Dulaglutide is primarily prescribed through traditional healthcare channels — endocrinologists, PCPs, and diabetes care centers. Telehealth platforms built around GLP-1 medications have not adopted dulaglutide for several reasons:
- Trulicity has no weight loss indication, so it sits outside most telehealth platforms' core use case
- No compounded dulaglutide market exists to offer cost-competitive pricing
- Semaglutide's stronger efficacy and dual diabetes/weight loss positioning makes it the default GLP-1 recommendation for most telehealth programs
If Trulicity is your current medication and you're seeking telehealth management for type 2 diabetes broadly, some general telehealth platforms (e.g., Teladoc, Amazon Clinic) may work with your existing prescriptions — but GLP-1 specialty telehealth platforms are built around semaglutide and tirzepatide.
For GLP-1 access through telehealth, semaglutide is the practical choice. Use our provider comparison tool to filter by medication, state, and price to find providers that match your needs.
How to Choose: A 3-Question Framework
1. Is this for diabetes management, weight loss, or both?
- Diabetes only: Both Trulicity and Ozempic are FDA-approved options. Discuss with your endocrinologist or PCP which fits your overall regimen.
- Weight loss or both: Semaglutide (Ozempic/Wegovy) has substantially better weight loss evidence. Trulicity is not the right tool for weight management.
2. Does cost matter significantly?
- If brand-name pricing with insurance is your path: both are similarly priced. Trulicity may be preferred by some providers for formulary reasons.
- If you need an affordable option or prefer to avoid insurance: compounded semaglutide through telehealth at $99–$450/month has no dulaglutide equivalent.
3. Do you want telehealth access?
- Telehealth: Semaglutide is widely available. Dulaglutide is not.
- Traditional care: Both are accessible through prescribers. Neither is harder to obtain in that channel.
Internal Comparison: Who Wins?
There is no universal "better" medication — but there is a clearer fit for most patients seeking telehealth access or weight management:
Choose semaglutide (Ozempic/Wegovy) if:
- Weight loss is a goal alongside or instead of blood sugar control
- You want telehealth access and lower monthly costs
- You want the broadest range of providers and pricing options
Trulicity may be the right choice if:
- You're already stabilized on dulaglutide with good A1C control and no desire to switch
- Your insurer covers Trulicity with a low copay and semaglutide is not covered
- Your endocrinologist has a clinical reason to prefer dulaglutide for your specific profile
For most patients exploring their options in 2026, semaglutide's combination of stronger efficacy data, weight loss benefit, and telehealth accessibility through compounded options makes it the more versatile GLP-1 choice. Trulicity remains a clinically sound diabetes medication — but the landscape has shifted around it.
Browse telehealth providers offering semaglutide and other GLP-1 medications on our full provider comparison page.
Frequently Asked Questions
Is Trulicity or Ozempic better for weight loss?
Ozempic (semaglutide) produces significantly more weight loss than Trulicity (dulaglutide). Head-to-head SUSTAIN-7 trial data showed semaglutide 1.0mg outperformed dulaglutide 1.5mg by 3.5 kg in average weight reduction. At higher doses used in the STEP trials (semaglutide 2.4mg via Wegovy), average weight loss exceeded 15% of body weight. Trulicity is not indicated for weight loss, and its weight reduction in diabetes trials averages 1.5–2 kg. If weight loss is your goal, semaglutide is the clinically supported choice.
Can I get Trulicity or Ozempic through telehealth?
Ozempic's active ingredient (semaglutide) is widely available through telehealth providers — often as a compounded injectable for $99–$450/month. Trulicity (dulaglutide) is rarely available through specialty GLP-1 telehealth platforms; it is primarily prescribed through traditional in-person care. If you want telehealth access to a once-weekly GLP-1 medication, semaglutide is the accessible option.
What is the cost difference between Trulicity and Ozempic?
Both Trulicity and Ozempic carry brand-name list prices of approximately $850–$1,000/month without insurance. The critical difference: compounded semaglutide (Ozempic's active ingredient) is available through telehealth providers for $99–$450/month. No comparable compounded option exists for dulaglutide (Trulicity). If cost is a significant factor, semaglutide through telehealth is materially more affordable.
What is the main difference between Trulicity and Ozempic?
Trulicity contains dulaglutide (Eli Lilly) and Ozempic contains semaglutide (Novo Nordisk). Both are once-weekly GLP-1 receptor agonists FDA-approved for type 2 diabetes. Key differences: semaglutide is more potent for A1C reduction and weight loss; it has a weight-management approved form (Wegovy); and it is available in compounded form through telehealth at a fraction of the brand price. Trulicity is a clinically effective diabetes medication but lacks semaglutide's telehealth accessibility and weight loss evidence base.